PrimBio Cancer HotSpot Panel
Clinical Genetic Test
Help
offered by
GTR Test Accession: Help GTR000561701.1
CANCERINHERITED DISEASEENDOCRINOLOGY ... View more
Last updated in GTR: 2018-09-10
Last annual review date for the lab: 2024-07-09 LinkOut
At a Glance
Screening
Chronic myelogenous leukemia, BCR-ABL1 positive; Acute lymphoid leukemia; Acute promyelocytic leukemia more...
ABL1 (9q34.12); AKT1 (14q32.33); ALK (2p23.2-23.1); APC (5q22.2); ATM (11q22.3) more...
Molecular Genetics - Targeted variant analysis: Next-Generation (NGS)/Massively parallel sequencing (MPS)
This panel is used to determine the genetic information (somatic …
Not provided
Not provided
Ordering Information
Offered by: Help
PrimBio Research Institute
View lab's website
Test Order Code: Help
6231
Contact Policy: Help
Post-test email/phone consultation regarding genetic test results and interpretation is provided to patients/families.
Pre-test email/phone consultation regarding genetic test results and interpretation is provided to patients/families.
Informed consent required: Help
Decline to answer
Pre-test genetic counseling required: Help
Decline to answer
Post-test genetic counseling required: Help
Decline to answer
Recommended fields not provided:
Conditions Help
Total conditions: 60
Condition/Phenotype Identifier
Test Targets
Genes Help
Total genes: 50
Gene Associated Condition Germline or Somatic Allele (Lab-provided) Variant in NCBI
Methodology
Total methods: 1
Method Category Help
Test method Help
Instrument *
Targeted variant analysis
Next-Generation (NGS)/Massively parallel sequencing (MPS)
* Instrument: Not provided
Clinical Information
Test purpose: Help
Screening
Target population: Help
This panel is used to determine the genetic information (somatic mutations) of a specific cancer or tumor, so that a physician, genetic counselor, or other health provider can offer the optimal treatment plan for a cancer patient.The variants detected in this assay are associated with many known cancers including breast, … View more
Recommended fields not provided:
Technical Information
Availability: Help
Tests performed
Entire test performed in-house
Analytical Validity: Help
The limit of detection is 3.5% allele frequency at 500X coverage and 5% allele frequency at 200X coverage. This technology cannot reliably detect mutations at coverage below 200X. Confirmation of actionable mutations should be performed by Sanger sequencing.
Proficiency testing (PT):
Is proficiency testing performed for this test? Help
No
Recommended fields not provided:
Regulatory Approval
FDA Review: Help
Not provided
Additional Information

IMPORTANT NOTE: NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.